Testing a new bleeding disorder treatment for young boys with hemophilia

This trial is testing a medication called fitusiran to see if it can help young boys with hemophilia A or B—a blood disorder that makes it hard for blood to clot—reduce their bleeding episodes. Some children in the study may have developed antibodies that make standard treatments less effective; this medication is designed to work even in those cases. The goal is to understand whether this treatment is safe and helpful for children this age.

Many boys with severe hemophilia struggle with frequent bleeding, and some develop antibodies that make traditional clotting factor treatments stop working. This trial exists to find out whether this medication can offer a better, more reliable way to prevent dangerous bleeds in young children.